ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 991,16
0,97%
Dow Jones
38 650,25
1,11%
DAX
18 049,96
0,81%
Brent Oil
83,475
-0,19%
Bitcoin
61 719,19
4,39%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Citius Pharmaceuticals Inc (CTXR)

  7. Citius Pharmaceuticals Inc (CTXR) Actualités

CTXR Citius Pharmaceuticals Inc

0,7101
0,0031 (0,44%)
Dernière mise à jour : 15:54:41
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Citius Pharmaceuticals Inc CTXR NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,0031 0,44% 0,7101 15:54:41
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,73 0,70 0,73 0,707
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
30/4/202422:05PRNUSCitius Pharmaceuticals Announces Closing of $15 Million..
26/4/202414:00PRNUSCitius Pharmaceuticals Announces $15 Million Registered..
11/4/202414:30PRNUSCitius Pharmaceuticals Announces Addition of City of Hope to..
04/4/202414:30PRNUSCitius Pharmaceuticals to Present at the LD Micro..
18/3/202413:30PRNUSCitius Pharmaceuticals Announces FDA Acceptance of the BLA..
07/3/202414:30PRNUSCitius Pharmaceuticals, Inc. Secures $2.4 million through..
04/3/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
26/2/202413:30PRNUSCitius Pharmaceuticals Announces Filing of Form S-3 Shelf..
23/2/202422:23EDGAR2Form S-3 - Registration statement under Securities Act of..
23/2/202422:18EDGAR2Form S-8 - Securities to be offered to employees in employee..
23/2/202414:30PRNUSCitius Pharmaceuticals to Participate in Upcoming BIO CEO..
15/2/202414:45EDGAR2Form 8-K - Current report
14/2/202422:40EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/2/202422:30PRNUSCitius Pharmaceuticals, Inc. Reports Fiscal First Quarter..
14/2/202415:18EDGAR2Form 8-K - Current report
14/2/202414:01PRNUSCitius Pharmaceuticals Resubmits the Biologics License..
26/1/202422:08EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
26/1/202422:05EDGAR2Form DEF 14A - Other definitive proxy statements
23/1/202422:05EDGAR2Form 8-K - Current report
23/1/202414:30PRNUSCitius Pharmaceuticals Announces Nomination of..
05/1/202422:05EDGAR2Form 8-K - Current report
02/1/202422:04EDGAR2Form 8-K - Current report
02/1/202414:31PRNUSCitius Pharmaceuticals Completes Enrollment in Pivotal Phase..
02/1/202414:30PRNUSCitius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023..
29/12/202322:05EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
09/11/202314:30PRNUSCitius Pharmaceuticals to Participate in the Sidoti..
31/10/202313:45PRNUSCitius Pharmaceuticals Announces Publication in Frontiers of..
24/10/202313:58EDGAR2Form 425 - Prospectuses and communications, business..
24/10/202313:53EDGAR2Form 8-K - Current report
24/10/202313:30PRNUSCitius Pharmaceuticals Executes Definitive Agreement to..
12/10/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/10/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/10/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/10/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/9/202322:30EDGAR2Form 8-K - Current report
21/9/202315:35GLOBEDawson James Securities Announces October Date for 8th..
18/9/202322:30PRNUSCitius Pharmaceuticals Reschedules Participation in Sidoti..
15/9/202322:30EDGAR2Form 8-K - Current report
13/9/202322:30PRNUSCitius Pharmaceuticals Mourns the Loss of Board Member,..
11/9/202315:53EDGAR2Form 8-K - Current report
08/9/202314:40EDGAR2Form 8-K - Current report
08/9/202314:00PRNUSCitius Pharmaceuticals, Inc. Receives Regulatory Guidance..
06/9/202322:30PRNUSCitius Pharmaceuticals to Participate in H.C. Wainwright and..
15/8/202315:25EDGAR2Form 8-K - Current report
14/8/202322:15PRNUSCitius Pharmaceuticals, Inc. Reports Fiscal Third Quarter..
14/8/202322:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202322:15EDGAR2Form 8-K - Current report
10/8/202314:37PRNUSCitius Pharmaceuticals Reaches 92 Event Milestone in..
31/7/202322:15EDGAR2Form 8-K - Current report
29/7/202322:16PRNUSCitius Pharmaceuticals, Inc. Receives a Complete Response..

Dernières Valeurs Consultées

NASDAQ
CTXR
Citius Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés